Zhongheng Group

The supplied evidence identifies the subject as Zhongheng Group and provides a website, but it does not establish the company’s business activities, products, history, ownership, headquarters, or operating markets. A keyword line in the evidence refers generally to traditional Chinese medicine and related brand categories; it does not explicitly connect those categories to Zhongheng Group. Accordingly, this dossier does not treat that line as confirmation of the company’s industry or offerings. Further verification from the company’s official materials or reliable reference sources is needed before describing its operations.

The supplied evidence does not provide a company history, founding date, founder, ownership changes, leadership information, or dated business milestones. It also does not establish that the general traditional Chinese medicine keywords in the source describe Zhongheng Group itself. No historical narrative can therefore be reliably written from the available material. The company’s website is supplied as a possible verification source, but no specific claims from its contents were provided here.

R&D and production of traditional Chinese patent medicines and chemical drugs

• 中成药 (Chinese patent medicines)

  Standardized traditional Chinese medicine formulations manufactured and sold by Zhongheng Group.

• 2015

  Former Chairman Xu Shuqing sentenced to 17 years for embezzlement and corporate bribery

  In August 2015, Zhongheng Group Chairman Xu Shuqing was placed under investigation on suspicion of corporate bribery; reports said she had close ties with Yu Yuanhui, former secretary of the Nanning Municipal Party Committee, who had been removed from office. In December 2020, the final ruling found her guilty of embezzlement, misappropriation of funds, and corporate bribery, and she was sentenced to 17 years in prison; about 787 million yuan in related state-owned equity gains were recovered, and she was ordered to return about 114.6 million yuan to Wuzhou Pharmaceutical.

  Source

Read more

• 2020.08.12

  Reported2020.08.12

  Zhongheng Group and Shenzhen Research Institute of Tsinghua University agree to establish an R&D center[5]中恒集团与深圳清华大学研究院签约共建研发中心finance.sina.com.cn

  Guangxi Wuzhou Zhongheng Group and Shenzhen Research Institute of Tsinghua University signed an agreement to jointly establish an R&D center, with cooperation covering platform development, commercialization of results, new-product R&D and talent development.

• 2020.08.07

  Reported2020.08.10

  Zhongheng Group receives industry awards and rankings[6]中恒集团荣获行业奖项并入选相关榜单finance.sina.com.cn

  At the 2020 China Pharmaceutical Industry Development Summit, Zhongheng Group received multiple 2019 industry awards and was ranked 58th among the 2019 top 100 Chinese pharmaceutical industrial companies and 16th among the 2019 top 50 growing Chinese pharmaceutical companies.

• 2019.11.25

  Reported2019.11.25

  Zhongheng Group announces its intention to acquire control of Laimei Pharmaceutical[7]中恒集团宣布拟取得莱美药业控制权finance.sina.com.cn

  Zhongheng Group announced that it intended to obtain control of Chongqing-listed Laimei Pharmaceutical. The report describes the acquisition as proposed and does not report its completion.

Read more

1. 1Official website supplied in subject recordzhongheng.com.cn
2. 2Former Chairman Xu Shuqing sentenced to 17 years for embezzlement and corporate briberythepaper.cn
3. 3Former Chairman Xu Shuqing sentenced to 17 years for embezzlement and corporate briberychinanews.com
4. 4Former Chairman Xu Shuqing sentenced to 17 years for embezzlement and corporate briberyepaper.cs.com.cn
5. 5中恒集团与深圳清华大学研究院签约共建研发中心finance.sina.com.cn
6. 6中恒集团荣获行业奖项并入选相关榜单finance.sina.com.cn
7. 7中恒集团宣布拟取得莱美药业控制权finance.sina.com.cn